直播预告 | 探秘皮尔法伯集团在制药领域的差异化竞争之路

9月7日10:00，领康医药集团创始人、董事长姜桥博士作客《医健创业谈》，将带来精彩的线上分享“大健康投资必读：减脂减重控糖新药趋势和投资解读”，敬请期待！

1

1.皮尔法伯制药公司及制药领域的发展策略和方向；

2.对中国制药行业的看法，在中国BD过程中遇到的挑战和建议；

3.集团大量投资于肿瘤学，是否考虑与外部生物医药公司合作，特定细分领域有何机会？

4.新冠疫情前后，美欧生物医药板块变化和如何促进皮尔法伯的业务发展？与欧美和中国项目的差异是什么？

5.预计在亚太市场，特别是中国，项目落地的时间、瘤种、开发阶段和合作模式如何？

6.集团的全球化布局策略和中国未来五年发展规划和业务重点是什么？

2

点击下方图片直达直播间

Julien Desgrippes

Head of Business Development Licensing, Medical Care

Julien has joined Pierre Fabre S.A. Business Development Team since November 2016. He has been working since then on a range of partnering opportunities and transactions to strengthen Pierre Fabre’s portfolio as well as to value internal R&D programs externally. His scope of interest encompasses R&D and commercial assets, within three therapeutic areas of focus: Oncology, Medical Dermatology and Rare Diseases. He has been directly involved in most of Pierre Fabre recent Business Development activities (Atara Biotherapeutics, Puma Biotechnology, CANbridge, Talem Therapeutics, Valenza Bio, Y Biologics etc.).

Before joining Pierre Fabre, Julien was working with AEC Partners, a strategic consulting and M&A boutique specialized in healthcare based in Paris France. He worked on several assignments across the world, not only related to the evaluation and valuation of assets and markets but also working on commercial and organizational problematics. His clients were large pharmaceutical companies, biotech, medtech, animal health or nutrition companies. 

Julien holds a Master of Science from HEC Paris, and is a Doctor of Pharmacy from Lyon 1 University.

敬请关注“美柏医健”公众号，及全新上线小程序，我们将围绕创业者的需求提供陪伴式的知识服务：创业辅导、园区选址、资源链接、风险投资、投融资对接、人才搭建、政策解读、知识平台、创业者社群等。